ClinicalTrials.Veeva

Menu
C

Chatham County Health Department | Clinical Trials Unit

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Emtricitabine
Tenofovir Alafenamide
TAF
Lenacapavir
Islatravir
Bictegravir
Rilpivirine
FTC
ISL
Doravirine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 25 total trials

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

The study will have two parts: Part A and Part B. In Part A, the goal of the study is to compare the effectiveness of switching to the study drugs GS...

Enrolling
HIV-1-infection
Drug: Lenacapavir Injection
Drug: GS-3242 Injection

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting
HIV-1 Infection
Drug: ISL/LEN FDC
Drug: B/F/TAF

The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvim...

Enrolling
HIV Infections
Drug: Cabotegravir
Drug: Teropavimab

The goal of this clinical study is to learn more about the experimental drugs lepetegravir and lenacapavir pacfosacil; to compare the combination of...

Active, not recruiting
HIV-1-Infection
Drug: Lepetegravir
Drug: Lepetegravir/Lenacapavir pacfosacil FDC

The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LE...

Active, not recruiting
HIV-1-Infection
Drug: Antiretroviral Combinations
Drug: ISL/LEN

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting
HIV-1-infection
Drug: Optimized Background Regimen (OBR)
Drug: Oral Lenacapavir Placebo

Trial sponsors

Gilead Sciences logo
Merck Sharp & Dohme (MSD) logo
Janssen (J&J Innovative Medicine) logo
ViiV Healthcare logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems